Subchronic Oral Toxicity Study of Mixed Tocopheryl Phosphates in Rats

Rats were fed diets containing 0%, 1 %, 3%, or 5% mixed tocopheryl phosphates for 90 days. No abnormal clinical signs related to treatment appeared. Some statistically significant changes in hematology and clinical chemistry parameters appeared, but the majority were not dose dependent, occurred in only one sex or group, and/or remained within the historical control range for this strain of rat. A statistically significant apparent reduction in blood protein was observed in animals treated with the tocopheryl phosphates, but further investigation showed that the test substance interfered with the protein assay. Repeat analysis using a method unaffected by plasma test substance levels showed no difference in plasma proteins among all groups. Gross necropsy revealed no abnormalities; reduced relative heart and epididymal weights were observed, but were not dose dependent and were considered incidental. Histopathological changes occurred only in the mesenteric lymph node and small intestine. Foreign material in a crystal-like form appeared in macrophages in both organs, and increased in a dose-related fashion. In the lymph node, sinus histiocytosis increased with dose, but the severity was similar between the control and low-dose groups. Foreign-body granulomatous inflammation, associated with Maltese cross birefringence of the crystals was seen in the mid- and high-dose animals, but not the low-dose group. Similarly, the small intestine showed increasing amounts of foreign material and inflammation in the mid- and high-dose but not in the 1 % diet. The 1 % diet (equivalent to 587 and 643 mg mixed tocopheryl phosphates/kg body weight/day for male and female rats, respectively) was considered the no observed adverse effect level.

Evaluation of the safety of mixed tocopheryl phosphates (MTP)—A formulation of α-tocopheryl phosphate plus α-di-tocopheryl phosphate

The safety of a formulation of mixed tocopheryl phosphates, (MTP) was evaluated in a series of toxicological tests in vivo using rats, mice and rabbits and in vitro using bacterial and mammalian cell cultures. The tests conducted included an oral LD(50) study, three 28-day oral repeat-dose studies, two dermal toxicity tests, an ocular irritation test, mutagenic potential tests, and chromosomal aberrations tests. MTP consists of mono alpha-tocopheryl phosphate (TP) and di-tocopheryl phosphate (T(2)P) and is intended for use as a dietary supplement and for dermal applications in humans and animals. The dermal and oral LD(50) values of MTP were determined to be >1130 mg/kg bw (918 mg tocopherol equivalents/kg bw) in rabbits and rats, respectively. MTP was not a dermal or eye irritant in rabbits and showed no allergenic potential in mice. In the mutagenicity and genotoxicity studies, MTP did not increased the number of revertants in Salmonella typhimurium or Escherichia coli and did not induce chromosomal aberrations in cultured Chinese hamster ovary (CHO) cells. When administered daily for 28 days by gavage at doses up to 955 mg/kg bw/day (780 mg tocopherol equivalents/kg bw/day), MTP produced no consistent, dose-dependent adverse effects in rats.

The conformational and biological analysis of a cyclic anti-obesity peptide from the C-terminal domain of human growth hormone

The three-dimensional solution structure of antiobesity drug (AOD), a 15-residue, disulfide-bonded, cyclic peptide, cyclo(6,13)-H2N-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH, derived from the C-terminal domain of the human growth hormone (hGH) (residues 177-191) was determined using two-dimensional 1H NMR spectroscopy. AOD stimulates lipolysis and inhibits lipogenesis, in vitro, in rodent, porcine and human adipose tissues. These biological effects suggest that AOD is a potential therapeutic candidate for the treatment of obesity. Conformational studies of AOD were conducted in aqueous solution and in water/dimethylsulfoxide mixtures. In general, spectral quality was superior in the water/ dimethylsulfoxide mixtures. The cyclic region of AOD in water/dimethylsulfoxide adopts type I beta-turns at residues Ser8-Val9-Glu10-Gly11 and Ser12-Cys13-Gly14-Phe15, each preceded by loop-like structures. Comparison of the conformation of this peptide with residues 177-191 in the native hGH protein X-ray crystal structure indicates that the synthetic peptide retains some structural similarity to the intact protein. This study provides evidence that the C-terminal region of hGH is a specific functional domain of the multifunctional hGH protein.

Studies on the use of "slimax", a chinese herbal mixture, in the treatment of human obesity

A phytochemical preparation known as "Slimax" was administered orally to human volunteers for a six week period, using a double-blind experimental method. This preparation is an aqueous extract of the Chinese medicinal plants Hordeum vulgare , Polygonatum multiflorum , Dimocarpus longan , Ligusticum sinense , Lilium brownii and Zingiber officinale . Treatment with Slimax resulted in a significant decrease in parameters such as body weight, waist and hip circumference, and Body Mass Index (BMI), in all subjects tested. The basis of action was shown to be through modification of lipid metabolism, with significant effects on both the accumulation and the release of lipid from adipose tissue. The experimental results indicate a great potential for the use of this herbal preparation in treatment of human obesity.

Effects of genetic and diet-induced obesity on lipid metabolism

C57BL/6J obese (ob/ob) and lean mice fed ad libitum on a normal mouse chow diet (Normal), were compared with lean mice of the same age and strain fed ad libitum on a high-fat diet, consisting of the Normal diet with the addition of beef lard (Lard), from age 3 months for 34 days. The lard-fed mice were seen to have significantly higher (P<0.05) body weight in this 34-day period than that of the other two groups fed on the Normal diet. Epididymal fat depot and adipocyte cell size were significantly larger (P<0.05) in the Lard-fed lean mice and in the obese (ob/ob) mice than were those of the Normal-fed lean mice. Dietary Lard intake did not significantly affect concentrations of plasma triglyceride although those of plasma cholesterol were significantly increased (P<0.05). The development of obesity in these Lard-fed mice appeared to be accelerated and significant.